PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND METHODS OF USE THEREOF FOR MODULATION OF THE MICROBIOME
First Claim
Patent Images
1. A method of reducing inflammation in a subject, comprising administering to the subject a probiotic composition comprising an isolated, anti-inflammatory bacterial population, such that inflammation in the subject is reduced.
7 Assignments
0 Petitions
Accused Products
Abstract
Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent disorders of the local or systemic microbiome in a subject are also provided.
145 Citations
128 Claims
- 1. A method of reducing inflammation in a subject, comprising administering to the subject a probiotic composition comprising an isolated, anti-inflammatory bacterial population, such that inflammation in the subject is reduced.
-
36. (canceled)
- 37. A method of treating a distal dysbiosis in a subject, comprising administering to the subject a probiotic composition comprising an isolated bacterial population in an amount sufficient to alter the microbiome at a site distal to the site of administration, engraftment, or colonization, such that the distal dysbiosis is treated.
-
44-50. -50. (canceled)
-
52-53. -53. (canceled)
-
55-61. -61. (canceled)
-
63-69. -69. (canceled)
- 70. A method of reducing intestinal permeability in a subject, comprising administering to the subject a probiotic composition comprising an isolated bacterial population, wherein administration of the probiotic composition augments a species of bacteria that produces short chain fatty acids, mucin, or a combination thereof, such that the intestinal permeability of the subject is reduced.
-
71-79. -79. (canceled)
-
81-120. -120. (canceled)
- 121. A pharmaceutical composition comprising an isolated anti-inflammatory bacterial population capable of decreasing secretion of pro-inflammatory cytokines and/or increasing secretion of anti-inflammatory cytokines by human peripheral blood mononuclear cells (PBMCs), and a pharmaceutically acceptable excipient.
-
128-133. -133. (canceled)
Specification